High-Dose Oral Vitamin D Supplementation and Risk of Falls in Older Women

Abstract STURDY was a Bayesian, response-adaptive trial with dose-finding and confirmatory stages. Participants (n=688; ≥70years with serum 25(OH)D of 10-29ng/mL) were randomized to 200 (control), 1000, 2000, or 4000 IU/day of vitamin D3. The primary outcome was time to first fall or death over 2 years. During dose-finding, the best non-control dose was determined to be 1000IU/day based on higher primary outcome event rates in the 2000 and 4000IU/day doses than the 1000IU/day dose (posterior probability of being best dose=0.90; hazard ratios[HR] were 1.86 [95%CI: 1.16-2.97] and 1.68 [95%CI: 1.05-2.69], respectively). Participants were then switched from other non-control doses to 1000IU/day, and event rates did not differ between the pooled higher doses and control groups (HR=1.02, P=0.84). There was no heterogeneity by baseline 25(OHD). In conclusion, high-dose vitamin D supplementation ≥1000IU/day did not prevent falls. Whether vitamin D doses >2000IU/day increase the risk of falls is uncertain.

Download Full-text

Administration of annual oral high-dose vitamin D to community dwelling older women in autumn and winter months increases risk of falls and fractures

Evidence-Based Nursing ◽

10.1136/ebn.13.4.123 ◽

2010 ◽

Vol 13 (4) ◽

pp. 123-124

Author(s):

C. R. Kessenich

Keyword(s):

Vitamin D ◽

Older Women ◽

Community Dwelling ◽

High Dose ◽

Risk Of Falls ◽

Autumn And Winter ◽

High Dose Vitamin

Download Full-text

Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

Multiple Sclerosis Journal ◽

10.1177/1352458516654310 ◽

2016 ◽

Vol 23 (3) ◽

pp. 395-402 ◽

Cited By ~ 32

Author(s):

Egil Røsjø ◽

Andreas Lossius ◽

Nada Abdelmagid ◽

Jonas C Lindstrøm ◽

Margitta T Kampman ◽

...

Keyword(s):

Vitamin D ◽

Epstein Barr Virus ◽

High Dose ◽

Oral Vitamin ◽

Barr Virus ◽

Relapsing Remitting ◽

Dose Oral ◽

Epstein Barr ◽

Antibody Levels ◽

Relapsing Remitting Multiple Sclerosis

Background: Elevated antibody levels against Epstein–Barr virus (EBV) and a poor vitamin D status are environmental factors that may interact in relapsing-remitting multiple sclerosis (RRMS) aetiology. Objectives: To examine effects of high-dose oral vitamin D3 supplementation on antibody levels against EBV nuclear antigen 1 (EBNA1) in RRMS. Methods: Serum 25-hydroxyvitamin D3 (25(OH)D) and immunoglobulin G antibody levels against EBNA1 (whole protein and amino acid 385–420 fragment), EBV viral capsid antigen (VCA), cytomegalovirus (CMV) and varicella zoster virus (VZV) were measured in 68 RRMS patients enrolled in a 96-week randomised double-blinded placebo-controlled clinical trial of oral vitamin D3 supplementation (20,000 IU/week) (NCT00785473). Results: The mean 25(OH)D level more than doubled in the vitamin D group and was significantly higher than in the placebo group at study conclusion (123.2 versus 61.8 nmol/L, p < 0.001). Compared to the placebo group, both anti-EBNA1 protein and fragment antibody levels decreased in the vitamin D group from baseline to week 48 ( p = 0.038 and p = 0.004, respectively), but not from baseline to week 96. Vitamin D3 supplementation did not affect antibodies against VCA, CMV or VZV. Conclusion: The results indicate that high-dose oral vitamin D3 supplementation can affect humoral immune responses against the latent EBV antigen EBNA1 in RRMS.

Download Full-text